Browse News
Filter News
Found 70 articles
-
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
4/23/2024
ImmunityBio, Inc., an immunotherapy company, announced that the U.S. Food and Drug Administration has approved ANKTIVA plus Bacillus Calmette-Guérin for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
-
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
2/27/2024
CG Oncology, Inc. today announced the first patient has been dosed in the PIVOT-006 Phase 3 clinical trial of cretostimogene for the treatment of patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
-
Prokarium Achieves Major Milestone with FDA's IND Approval for Bladder Cancer Program
11/2/2023
Prokarium announces that the U.S. Food and Drug Administration has granted the company's Investigational New Drug application for their immunotherapy ZH9.
-
Photocure: Nordic registry clinical data and multiple scientific programs at AUA 2023 Congress reinforce the benefits of Blue Light Cystoscopy
5/2/2023
Photocure ASA, the Bladder Cancer Company, announces that results from the Nordic Registry demonstrating benefits of Blue Light Cystoscopy were presented at the AUA 2023 Conference: the American Urological Association Annual Congress 2023 which was held April 28 - May 1, 2023 in Chicago, IL, USA.
-
New Studies on Convergent Genomics' Urine Test for Bladder Cancer to be Presented at 2023 American Urological Association (AUA) Annual Meeting
4/25/2023
Convergent Genomics announced UroAmp, the company's genomic urine test that uses next-generation DNA sequencing and machine learning to detect and monitor for bladder cancer, will be the subject of two new studies being presented at the 2023 American Urological Association (AUA) Annual Meeting in Chicago.
-
Verana Health Announces Release of Qdata Module for Non-Muscle Invasive Bladder Cancer RWE Analysis
2/13/2023
Verana Health®—a digital health company elevating quality in real-world data (RWD)—today announced that a Urology Qdata® module is available to help support clinical research surrounding non-muscle invasive bladder cancer (NMIBC).
-
Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy
1/31/2023
Istari Oncology, Inc. today announced the first patient has been dosed via intravesicular instillation in the non-muscle-invasive bladder cancer (NMIBC) cohort of the LUMINOS-103 basket trial.
-
DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience
1/5/2023
DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, and Nonagen Bioscience Corporation (“Nonagen”), a cancer diagnostics company, today announced the successful completion of the validation study of Oncuria® multiplex bladder cancer immunoassay as a laboratory developed test (“LDT”).
-
CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline
11/15/2022
CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced the close of an oversubscribed $120 million Series E financing round.
-
Sickle Cell Disease (SCD) Treatment Market Size, Share Analysis and Growth Forecast 2030 - Reports and Data
10/6/2022
The global sickle cell disease treatment market size was USD 1.70 Billion in 2021 and is expected to register a revenue CAGR of 18.1% over the forecast period, according to the latest report by Reports and Data.
-
Dystrophic Epidermolysis Bullosa Treatment Market: Regional Outlook, Competitive Strategies & Forecast up to 2030 | Reports and Data
10/4/2022
The latest market analysis report published by Reports and Data, titled ‘Global Dystrophic Epidermolysis Bullosa Treatment Market – Forecast to 2030,’ thoroughly examines the Dystrophic Epidermolysis Bullosa Treatment industry to provide essential data & information for the targeted readers.
-
Rising Patient Numbers, And Increase In Public Knowledge Of The Infection Are Expected To Drive Pseudomonas Aeruginosa Infection Treatment Market Growth By 2030 | Reports And Data
9/29/2022
The latest market analysis report published by Reports and Data, titled ‘Global Pseudomonas Aeruginosa Infection Treatment Market – Forecast to 2030’ thoroughly examines the Pseudomonas Aeruginosa Infection Treatment Market industry to provide essential data & information for the targeted readers
-
Major Depressive Disorder Market Hold A High Potential For Growth By 2030 - Reports and Data
9/13/2022
The latest market analysis report published by Reports and Data, titled ‘Global Major Depressive Disorder Market – Forecast to 2030,’ thoroughly examines the Major Depressive Disorder industry to provide essential data & information for the targeted readers.
-
Single Cell Analysis Market Growth, Shares, Future Trends and Key Countries by 2027
8/19/2022
The global Single Cell Analysis Market is forecasted to reach USD 6.98 Billion by 2027, according to a new report by Reports and Data.
-
The BLA is for the use of the drug N-803 with BCG to treat patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma with or without Ta or T1 disease.
-
Lennox Gastaut Syndrome Market Regional Growth Analysis With Industry Players Data By 2030
7/29/2022
Forecast to 2030,’ thoroughly examines the Lennox Gastaut Syndrome industry to provide essential data & information for the targeted readers.
-
Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US
7/18/2022
Sesen Bio (Nasdaq: SESN ) today announced that it has made the strategic decision to voluntarily pause further development in the US of its lead asset, Vicineum.
-
BCG Vaccines Market: Rapid Advancements in Technology in the Field of Medical Research on Vaccines to Drive the Market
6/24/2022
Wilmington, Delaware, United States: Currently, BCG vaccine is the only available vaccine for tuberculosis.
-
Industrial Biotechnology Market Growth 2022-2030: Rising Concerns About Greenhouse Gas Emission, High Crude Oil Prices, And Low Biofuel Costs
6/3/2022
The global industrial biotechnology market size is expected to reach USD 852.55 Billion in 2030 and register a revenue CAGR of 9.9% over the forecast period, according to the latest report by Reports and Data.
-
Live Vaccines Market Growth by 2026: Increasing Awareness Among the Population, Rising Governmental Initiatives, Increasing Healthcare Spending Capacity of Individuals
6/1/2022
Live Vaccines Market size was USD 16.14 billion in 2019 and is predicted to grow at a CAGR of 6.6% through the forecast period to reach over USD 24.95 billion by 2026.